Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Lannett Company, Inc. (NYSE: LCI).

On November 3, 2016, Bloomberg published an article titled "U.S. Charges in Generic-Drug Probe to Be Filed by Year-End," which reported that an "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies," including Lannett, "and about two dozen drugs." The article further stated that a "grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year." Additionally, according to Bloomberg, "[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General" who "is seeking to lead a group of states to probe the industry, which could result in cases seeking damages."

KSF's investigation is focusing on whether Lannett's officers and/or directors breached their fiduciary duties to Lannett's shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Lannett shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers